Xvivo Perfusion AB (LTS:0RKL)
kr 471.13141 -2.4818 (-0.52%) Market Cap: 15.12 Bil Enterprise Value: 14.69 Bil PE Ratio: 73.15 PB Ratio: 7.28 GF Score: 89/100

Full Year 2020 Xvivo Perfusion AB Earnings Call Transcript

Jan 28, 2021 / 01:00PM GMT
Release Date Price: kr270.5 (-4.59%)
Operator

Welcome to the XVIVO Perfusion Report On Operations 2020 Webcast.

I will now hand over to CEO, Dag Andersson. Please go ahead with your meeting.

Dag Andersson;publ;President;CEO
Xvivo Perfusion AB

()-&

Thank you very much. So Dag Andersson, CEO of XVIVO; and Kristoffer Nordstrom, CFO of XVIVO. We are here in Gothenburg today, and we are going to talk about the fourth quarter performance and also summarize 2020 and then talk a little bit about 2021.

I will start by talking a little bit about the highlights, quarter 4. All in all, I am happy with the quarter, I'm happy with the year. Despite the pandemic, we made a lot of progress. And I'm going to show you here a little bit of what our main achievements were, especially in quarter 4. We managed to get the first patients included in the EU Heart preservation study. 4 centers out of 9 are ready to include patients. And we have had patients in Belgium and also at Sahlgrenska Hospital here in Gothenburg, Sweden. So that's a real highlight.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot